Inventor · disambiguated record
Joerg Benz
Also filed as: BENZ JOERG
16 granted patents·31 pending applications·33 citations·filing 2006–2024
90Inventor score
Top patents by PatentIndex Score
47 records- 0194US11420961B2Heterocyclic compoundsHOFFMANN LA ROCHE·Filed 2020·Granted Aug 23, 2022·6 cites·19 claims
- 0292US11802133B2Heterocyclic compounds as monoacylglycerol lipase inhibitorsHOFFMANN LA ROCHE·Filed 2022·Granted Oct 31, 2023·2 cites·10 claims
- 0392US11608347B2Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitorsHOFFMANN LA ROCHE·Filed 2020·Granted Mar 21, 2023·4 cites·30 claims
- 0492US11390610B2Piperazine derivatives as MAGL inhibitorsHOFFMANN LA ROCHE·Filed 2020·Granted Jul 19, 2022·6 cites·38 claims
- 0591US11981661B2Heterocyclic compoundsHOFFMANN LA ROCHE·Filed 2021·Granted May 14, 2024·2 cites·17 claims
- 0690US11814375B2Heterocyclic compoundsHOFFMANN LA ROCHE·Filed 2020·Granted Nov 14, 2023·2 cites·17 claims
- 0783US2024294642A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 0882US9562091B2Humanized anti-Tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2014·Granted Feb 7, 2017·4 cites·10 claims
- 0981US12281124B2Heterocyclic compounds as monoacylglycerol lipase inhibitorsHOFFMANN LA ROCHE·Filed 2023·Granted Apr 22, 2025·0 cites·20 claims
- 1081US11192957B2Antibodies binding to HLA-A2/WT1HOFFMANN LA ROCHE·Filed 2018·Granted Dec 7, 2021·2 cites·38 claims
- 1181US2023183349A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1281US2025129179A1Antibodies binding to hla-a2/wt1HOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1380US10465000B2Humanized anti-Tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Nov 5, 2019·2 cites·6 claims
- 1479US2024101657A1Antibody that binds to vegf and il-1beta and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1578US10517945B2Covalently linked antigen-antibody conjugatesHOFFMANN LA ROCHE·Filed 2014·Granted Dec 31, 2019·3 cites·16 claims
- 1678US2023143310A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1775US12098213B2Antibodies binding to HLA-A2/WT1HOFFMANN LA ROCHE·Filed 2021·Granted Sep 24, 2024·0 cites·40 claims
- 1873US11866490B2Antibody that binds to VEGF and IL-1beta and methods of useHOFFMANN LA ROCHE·Filed 2021·Granted Jan 9, 2024·0 cites·36 claims
- 1971US11130804B2Antibody that binds to VEGF and IL-1beta and methods of useHOFFMANN LA ROCHE·Filed 2019·Granted Sep 28, 2021·0 cites·28 claims
- 2070US2023183224A1Bezoxazine derivatives useful as monoacylglycerol lipase inhibitorsHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2167US2024383904A1Heterocyclic compoundsHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2266US12023378B2Covalently linked antigen-antibody conjugatesHOFFMANN LA ROCHE·Filed 2019·Granted Jul 2, 2024·0 cites·21 claims
- 2366US2025163139A1Antibody that binds to vegf-a and il6 and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2466US2023117324A1Oxazine monoacylglycerol lipase (magl) inhibitorsHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2565US2020223912A1Humanized anti-tau(ps422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2665US2020308190A1Heterocyclic compounds as monoacylglycerol lipase inhibitorsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2764US2024199587A1Heterocyclic compoundsHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2863US2022106328A1Heterocyclic compoundsHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2962US2022267349A1Heterocyclic compoundsHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3062US2025059185A1Bicyclic heterocyclic compounds useful as monoacylglycerol lipase inhibitorsHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3162US2023203056A1Heterocyclic compoundsHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 3262US2019382489A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 3361US2025099448A1Heterocyclic compoundsHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 3458US2021094972A1Heterocyclic compoundsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3558US2021107920A1Oxazine monoacylglycerol lipase (magl) inhibitorsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3657US2020308158A1Bezoxazine derivatives useful as monoacylglycerol lipase inhibitorsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3756US2017247454A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 3856US2022220373A1Fluorescent probes for monoacylglycerol lipase (magl)HOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3956US2021107921A1Heterocyclic compoundsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 4056US2022213093A1Heterocyclic monoacylglycerol lipase (magl) inhibitorsHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4155US2022002397A1Method for improving inhibition of vegf-binding to vegf-r1 of an anti-vegf antibodyHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4255US2022135591A1Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl)HOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4352US2021277020A1Heterocyclic compounds as monoacylglycerol lipase inhibitorsHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4446US2022325265A1Glucocerebrosidase mutantsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 4540US8309340B2Insulin degrading enzyme crystalsBENZ JOERG·Filed 2008·Granted Nov 13, 2012·0 cites·4 claims
- 4636US2011060580A1Lxr ligand binding domain (lxr lbd) crystalsBENZ JOERG·Filed 2009·Application pending·0 cites
- 4729US2007048853A1Carnitine palmitoyltransferase II crystalsBENZ JOERG·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Joerg Benz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →